0000000000725591

AUTHOR

Giovanni Cenderello

showing 7 related works from this author

Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

2022

Abstract Background In persons living with HIV (PLWH), the burden of non-communicable chronic diseases increased over time, because of aging associated with chronic inflammation, systemic immune activation, and long-term exposure to the combination antiretroviral therapy (ART). Methods To explore the association of chronological age, age at first ART, and exposure to ART with non-communicable chronic diseases, we performed a cross-sectional analysis to evaluate the prevalence of comorbidities in patients enrolled in the SCOLTA Project, stratified by groups of chronological age (50–59 and 60–69 years) and by years of antiretroviral treatment (ART, ≤ 3 or > 3 years). Results In 1394 subjec…

Cross-Sectional StudieMaleART exposureHIVMultimorbidityHIV InfectionsComorbidityOsteoporosis.Noncommunicable DiseaseBone Diseases MetabolicCross-Sectional StudiesInfectious DiseasesAgeAnti-Retroviral AgentsHypertensionHumansOsteoporosisAnti-Retroviral AgentFemaleHIV InfectionNoncommunicable DiseasesAgedHuman
researchProduct

Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C rea…

2019

Previous article in issueNext article in issue Introduction: There is a limited documentation about the retreatment of patients failing a recommended NS5A-containing regimen in Italy. Materials & methods: Within the VIRONET-C network, 386 NS5A-failing patients infected with different HCV-genotypes (GT) (GT1a/1b/2a-c/3a-b-g-h/4a-d-n-o-v=93/124/19/112/38) were analyzed. Retreatment of 105 failures was investigated. HCV-resistance-test was performed by Sanger-sequencing. Results: Failures following seven different NS5A-containing regimens were studied: 3D/2D (paritaprevir/ombitasvir ± dasabuvir) ± ribavirin (N = 72/4), daclatasvir/ledipasvir/velpatasvir + sofosbuvir ± ribavirin (N = 105/13…

Resistance testmedicine.medical_specialtyHepatologybusiness.industryGastroenterologyDAA failurVironet C.NS5ARegimenInternal medicinemedicineretreatmentNS5AbusinessDigestive and Liver Disease
researchProduct

Factors Associated With Weight Gain in People Treated With Dolutegravir.

2020

AbstractBackgroundAn unexpected excess in weight gain has recently been reported in the course of dolutegravir (DTG) treatment. The aim of the present study was to investigate whether weight gain differs among different DTG-containing regimens.MethodsAdult naïve and experienced people with HIV (PWH) initiating DTG-based antiretroviral therapy (ART) between July 2014 and December 2019 in the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) prospective cohort were included. We used an adjusted general linear model to compare weight change among backbone groups and a Cox proportional hazard regression model to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for …

0301 basic medicinemedicine.medical_specialtyWeight gain.HIV metabolic complications030106 microbiologyHIV metabolic complicationTDFEmtricitabineTenofovir alafenamidedolutegravir HIV metabolic complications TAF TDF weight gain.03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAbacavirInternal medicinemedicineMajor Article030212 general & internal medicinebusiness.industryWeight changeLamivudineweight gaindolutegravirInfectious DiseasesAcademicSubjects/MED00290OncologychemistryTAFRilpivirineDolutegravirmedicine.symptombusinessWeight gainmedicine.drugOpen forum infectious diseases
researchProduct

Five-year retrospective italian multicenter study of visceral leishmaniasis treatment.

2014

ABSTRACT The treatment of visceral leishmaniasis (VL) is poorly standardized in Italy in spite of the existing evidence. All consecutive patients with VL admitted at 15 Italian centers as inpatients or outpatients between January 2004 and December 2008 were retrospectively considered; outcome data at 1 year after treatment were obtained for all but 1 patient. Demographic characteristics, underlying diseases, diagnostic procedures, treatment regimens and outcomes, as well as side effects were recorded. A confirmed diagnosis of VL was reported for 166 patients: 120 (72.3%) immunocompetent, 21 (12.6%) patients with immune deficiencies other than HIV infection, and 25 (15.1%) coinfected with HI…

AdultMalemedicine.medical_specialtySettore MED/17 - Malattie InfettiveAdolescentAntiprotozoal AgentsSocio-culturaleClinical TherapeuticsAdolescent; Adult; Aged; Amphotericin B; Antiprotozoal Agents; Child; Female; Humans; Italy; Leishmaniasis Visceral; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult; Pharmacology (medical); Pharmacology; Infectious DiseasesYoung AdultAmphotericin BInternal medicineAmphotericin BmedicineHumansPharmacology (medical)Young adultvisceral leishmaniasis treatment ItalyChildLeishmaniasisAgedRetrospective StudiesVisceralPharmacologybusiness.industryAmbientaleRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryInfectious DiseasesVisceral leishmaniasisTreatment OutcomeMulticenter studyItalyLeishmaniasis VisceralLiposomal amphotericinFemaleOutcome databusinessAfter treatmentmedicine.drug
researchProduct

Can the Multidimensional Prognostic Index Improve the Identification of Older Hospitalized Patients with COVID-19 Likely to Benefit from Mechanical V…

2022

Objective: Data on prognostic tools for indicating mechanical ventilation in older people with COVID-19 are still limited. The aim of this research was to evaluate if the Multidimensional Prognostic Index (MPI), based on the Comprehensive Geriatric Assessment (CGA), may help physicians in identifying older hospitalized patients affected by COVID-19 who might benefit from mechanical ventilation.Design: Longitudinal, multicenter study.Settings and Participants: 502 older people hospitalized for COVID-19 in 10 European hospitals.Methods: MPI was calculated using 8 different domains typical of the CGA. A propensity score, Cox's regression analysis was used for assessing the impact of mechanical…

Aged 80 and overHealth PolicyCOVID-19HumansProspective StudiesGeneral MedicineCOVID-19 Comprehensive Geriatric Assessment Multidimensional Prognostic Index mechanical ventilation mortalitynoninvasive ventilation prognosisGeriatrics and GerontologyPrognosisGeriatric AssessmentRespiration ArtificialGeneral NursingAgedJournal of the American Medical Directors Association
researchProduct

Epidemiology, aetiology and treatment of skin and soft tissue infections: final report of a prospective multicentre national registry

2022

Skin and soft tissue infections (SSTIs) represent a heterogenous group of pathological conditions involving the skin or the underlying subcutaneous tissues, fascia and muscle, characterised by a considerable variety of clinical presentations, severity and possible aetiological pathogens. Although previous analyses on restricted types of SSTIs and population have already been published, we conducted a large nationwide surveillance program on behalf of the Italian Society of Infectious and Tropical Diseases to assess the clinical and microbiological characteristics of the whole SSTI spectrum, from mild to severe life-threatening infections, in both inpatients and outpatients and their managem…

PharmacologyAdultRegistrieSoft Tissue InfectionsSoft Tissue Infections.SSTIComorbidityABSSSIregistryABSSSIs; SSTIs; registryABSSSIsAnti-Bacterial AgentsProspective StudieInfectious DiseasesOncologySSTIsItalyAnti-Bacterial AgentHumansPharmacology (medical)Prospective StudiesRegistriesHuman
researchProduct

Additional file 1 of Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

2022

Additional file 1: Table S1. Comorbidities by age class (%), comparison with the general Italian population.

researchProduct